A new kind of antibody targets a feature shared by proteins thought to cause the most damage in Alzheimer’s disease, Parkinson’s disease, and related conditions, creating potential for a unified treatment approach.
This is the finding of a study led by researchers from NYU School of Medicine and published online August 29 in Scientific Reports.
The new study is based on decades of work arguing that the contribution to disease of key proteins—amyloid beta and tau in Alzheimer’s disease, alpha-synuclein in Parkinson’s disease, and prion proteins in conditions like mad cow disease—is driven by certain, toxic forms dominated by a common structure: bundles of “beta sheets” in clumped proteins.
In tissues from autopsied patients with these diseases and in live mice, experiments demonstrated how the study antibodies target and remove only these toxic forms, say the authors, and without triggering the immune toxicity that has frustrated treatment development efforts to date.
“In an atmosphere where countless treatments have failed in clinical trials over the last 15 years, the fact that our approach continues to be effective in rigorous tests should be of interest to our peers and the industry, even if it runs contrary to conventional thinking,” says corresponding author Fernando Goni, PhD, research associate professor in the Department of Neurology at NYU Langone Health.
“While we still have a number of milestones to reach before this work is ready for clinical testing, our results suggest that these antibodies may halt key pathological mechanisms across several neurological diseases and regardless of disease stage,” says corresponding author Thomas Wisniewski, MD, director of NYU Langone’s Center for Cognitive Neurology, Silberstein Alzheimer’s Institute, and Alzheimer’s Disease Center.
New Approach to Antibody Design
The study focuses on proteins that form important structures in the brain. The instant they form as chains of amino acids, proteins fold into complex shapes needed to do their jobs. Unfortunately, proteins can also “misfold” for countless reasons, such as genetic abnormalities, toxins, age-associated cell processes, and inflammation that eventually cause the diseases addressed by the current study. Cells and tissues die as misshapen proteins stop working and build up, but the field has struggled to pinpoint which of these shifting forms to target as the key drivers of disease.
Many research efforts, including the current study, seek to design antibodies shaped to attach to and remove the right targets. Past and ongoing attempts have targeted the initial, short chains of amino acids that serve as basic, repeating structural units, or monomers, of each misfolded protein. Still others targeted end-stage fibrils, each made of thousands of monomers, which accumulate in plaques and tangles that tissues cannot eliminate. Neither approach has yielded an effective therapy.
In that light, Dr. Goni, Dr. Wisniewski, and colleagues designed their antibodies to target instead the “oligomers” formed as several misfolded monomers associate and acquire the “beta-sheet” shape, but before they are large enough to fibrilize. These intermediate forms may be uniquely toxic, say many in the field, because, unlike fibrils, they can dissolve, move in and out of cells, and from one cell to another. This mobility may explain the “prion-like” progression seen in misfolding diseases where abnormal proteins cause normal ones to misfold in a domino effect that damages nerve cells and their connections in the brain.
Importantly, growing toxic oligomers of amyloid beta, tau, alpha synuclein, and prion protein become increasingly dominated by the twisted strands of amino acids called beta sheets, which have spatial arrangements that let the strands stack up.
To design new kinds of antibodies, the research team zeroed in on a small 13-amino acid peptide, derived from the extremely rare genetic disease called British amyloidosis, but not present in the rest of the human population. They converted it into a larger, stable oligomer with more than 90 percent “beta-sheet” structure—the p13Bri immunogen—that could be “seen” by the mammalian immune system, and that could trigger a specific antibody response to solve problems encountered with standard approaches. By immunizing mice with p13Bri at high doses, they forced the production of extremely rare antibodies against beta sheets in toxic oligomers.
The researchers say that their rare antibodies, activated by a protein fragment seen only in a rare disease, have almost zero chance of triggering unwanted immune responses to normal proteins with similar sequences (autotoxicity), the downfall of many previous attempts. Finally, the team screened their lead antibodies against tissues taken from the brains of human patients with Alzheimer’s disease, Parkinson’s disease, and prion diseases. Only the six monoclonal antibodies that reacted to toxic oligomers from at least two misfolded proteins from two diseases were selected for further study.
“This publication details the first system for making antibodies that truly target only toxic oligomers of misfolded proteins dominated by beta sheets across several diseases, and without regard to the amino acid makeup of each misfolded protein’s monomer,” says Dr. Goni.
The Latest on: Neurological diseases
- Neurologist Dr. Deborah Boland Expands Telemedicine Services to Homebound Neurological Patientson March 21, 2020 at 12:02 am
Tampa, FL, March 21, 2020 --(PR.com)-- Between now and April 30, 2020, Dr. Deborah Boland, D.O., MSPT, a neurologist, movement disorder specialist, and owner of Be Mobile Neurology, is expanding ...
- Neurology Devices Market 2020-2024 | Increasing Prevalence of the Neurological Disorders to Boost Growth | Technavioon March 20, 2020 at 1:30 pm
Increasing prevalence of the neurological disorders has been instrumental in driving the growth of the market. Neurology Devices Market 2020-2024: Segmentation Neurology Devices Market is segmented as ...
- ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health and disease across more than 40 countrieson March 20, 2020 at 6:50 am
ENIGMA was launched in December 2009 to help ‘break the logjam’ in genetic studies of the brain. At the time, most neuroimaging genetics studies were assessing historically candidate genetic ...
- Neurologic Disorders Therapeutics Market Highlights on Future Development 2028 : Johnson & Johnson Services Inc., Novartis AG, Biogen Inc.on March 19, 2020 at 9:56 am
There are several factors that are influencing the growth of the global neurologic disorders therapeutics market. This press release was orginally distributed by SBWire San Francisco, CA -- ( SBWIRE) ...
- Hallervorden-Spatz Diseaseon March 18, 2020 at 10:18 am
It’s an inherited neurological disorder. It causes issues with movement. HSD is a very rare but serious condition that worsens over time and can be fatal. HSD causes a wide variety of symptoms that ...
- The ALS Association Awards Bloom Science to Develop Novel Gut Microbiota-based Therapies for Amyotrophic Lateral Sclerosis (ALS)on March 17, 2020 at 5:36 pm
Bloom Science, a biopharmaceutical company focused on the discovery and development of medicines tailored for individual patients living with neurological diseases, has received a $500,000 grant from ...
- The Market's Fatal Neurological Diseaseon March 16, 2020 at 5:06 pm
EUR/USD settles at 1.1170 despite risk-off led The EUR/USD pair closed the day with gains in the 1.1170 price zone, despite the greenback appreciated sharply against most rivals. Wall Street had ...
- Alzheimer’s Disease Diagnostic Market is to Witness Many Novel developments; MRFR Reveals Insights for 2016 – 2022on March 16, 2020 at 8:11 am
mainly due to the rising prevalence of the condition called Alzheimer’s disease (dementia). The growing occurrences of neurological diseases & disorders related to memory & thinking that could lead to ...
- Wild deer in Dakota County confirmed positive for chronic wasting diseaseon March 13, 2020 at 1:00 pm
A wild deer was confirmed positive for chronic wasting disease in Dakota County, marking the first detection of the fatal neurological disease in this area of the state, the Minnesota Department of ...
- Accurate Eye-Tracking and AI to Detect Neurological Diseases: Interview with Co-Founders of C. Lighton March 12, 2020 at 3:04 pm
Being diagnosed with any number of neurological diseases can be scary, not only due to the progressive nature of many of these conditions, but also because they often cannot be detected until their ...
via Google News and Bing News